IHC Management

Peter A. Fratarcangelo, Ph.D. – CEO

Peter Fratarcangelo has more than 40 years experience in the clinical research of Rx, OTC, & Rx-to-OTC switch compounds. As CEO of International HealthCare and International Pharmaceutical Research (a mid-size CRO), Peter has guided the research of more than 150 compounds. He has been successful in designing, coordinating and implementing entire clinical programs for 10 Rx-to-OTC switches & 7 Rx – NDA programs, 3 NCE agents, one biologic and two medical devices. As Director of Research, Peter successfully guided the clinical development and provided the pivotal research for many important new drugs now on the market.  Examples of such are:

  • Pepcid-AC®
  • Zantac-75®
  • Tagamet-HB®
  • Axid-AR®
  • Imodium-AD®
  • Carafate®
  • Gyne-Lotrimin®
  • Mycelex®
  • Nicorette Gum®
  • Children’s Motrin®
  • Angiomax®
  • Aricept®
  • Lorabid®
  • Preparation-H®
  • Maalox®
  • Massengill®
  • Zofran®
  • Immetrix®
  • Children’s & Extra Strength Tylenol®
  • Crest Sensitive®
  • Promise®
  • Aqua-Fresh Sensitive® toothpaste
  • Robaxin®

Peter has presented more than forty papers and clinical reports at symposiums and conferences covering the wide range of therapeutic areas evident in his research referenced above. Peter is also a frequent speaker at International Research Conferences, training the attendees on the design of clinical studies for Rx-to-OTC Switching, proper clinical site management and Good Clinical Practices. Before starting his CRO in 1984, Peter worked as Associate Director of Rx Clinical Research in the New Drug Development Department at Pfizer Pharmaceuticals and in the OTC arena as Associate Director-Personal Products at Richardson-Vicks, Inc. Peter holds a B.S. degree from Manhattan College, an MS from NYU, and a Ph.D. from CPU. He is an associate member of the CHPA, a member of the Drug Information Association and a charter member of the National Institute for Infectious Disease.

William K. Tobin – President

Bill Tobin has been IHC’s President since CRO inception in 2001.  Bill has been conducting and managing clinical trials for drugs, biologics, tissue and medical devices in a wide range of therapeutic areas since 1994. Prior to joining International HealthCare, Bill served as Clinical Project Manager at Purdue Pharma, LLP in Stamford, CT.  While at Purdue he managed a newly developed local anesthetic product and later was promoted to manage clinical trials for OxyContin. Initially entering the medical research field as a Clinical Research Associate at International Pharmaceutical Research, a CRO based in Norwalk, CT, Bill became key to the company’s growth to over 100 clinical scientists, SAS programmers and statisticians. His role and responsibilities included project planning, protocol development, investigator selection, project implementation and data analysis for many successful NDA programs. He also held positions as Project Manager and Associate Director of New Business Development. Bill has the unique experience as a clinical program manager for both a large Pharma and a mid-size CRO and has managed successful large scale domestic and international programs.

Bill is a member of various industry associations and maintains his knowledge of Good Clinical Practices and FDA guidance’s through continuous industry provided training.  A graduate of Providence College with a B.S. in biology, and MPH  in epidemiology from New York Medical College.